The effect of L-carnitine on oxidative stress responses of experimental contrast- induced nephropathy in rats

Journal of Veterinary Medical Science

Volumn 76, Issue 1, 2014, Pages 1-8

  Boyacioglu, Murat ^a   Turgut, Hulya ^a   Akgullu, Cagdas ^a   Eryilmaz, Ufuk ^a   Kum, Cavit ^a   Onbasili, Osman Alper ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

Antioxidant defense; Contrast induced nephropathy; L carnitine; Oxidative stress

Indexed keywords

CARNITINE; CATALASE; CONTRAST MEDIUM; CREATININE; GLUTATHIONE; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CYTOCHEMISTRY; DRUG EFFECT; ENZYMOLOGY; KIDNEY DISEASE; MALE; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; RANDOMIZATION; RAT; URINE; WISTAR RAT;

ANIMALS; CARNITINE; CATALASE; CONTRAST MEDIA; CREATININE; GLUTATHIONE; HISTOCYTOCHEMISTRY; KIDNEY DISEASES; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; RANDOM ALLOCATION; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

EID: 84893474452     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.13-0202     Document Type: Article

References (55)

1. Al-Majed, A. A. 2007. Carnitine deficiency provokes cisplatini{dotless}nduced hepatotoxicity in rats. Basic Clin. Pharmacol. Toxicol. 100: 145-150. [Medline] [CrossRef]
2. Arduini, A. 1992. Carnitine and its acetyl esters as secondary antioxidants. Am. Heart J. 123: 1726-1727. [Medline] [CrossRef]
3. Arockia, Rani P. J. and Panneerselvam, C. 2001. Carnitine as a free radical scavenger in aging. Exp. Gerontol. 36: 1713-1726. [Medline] [CrossRef]
4. Aspelin, P., Aubry, P., Fransson, S. G., Strasser, R., Willenbrock, R. and Berg, K. J. 2003. Nephrotoxic effects in high-risk patients undergoing angiography. N. Engl. J. Med. 348: 491-499. [Medline] [CrossRef]
5. Aureli, T., Miccheli, A., Di Cocco, M. E., Ghirardi, O., Giuliani, A., Ramacci, M. T. and Conti, F. 1994. Effect of acetyl-L-carnitine on recovery of brain phosphorus metabolites and lactic acid level during reperfusion after cerebral ischemia in the rat, Study by 31P-and 1H-NMR spectroscopy. Brain Res. 643: 92-99. [Medline] [CrossRef]
6. Ay, T., Havaux, X., Van Camp, G., Campanelli, B., Gisellu, G., Pasquet, A., Denef, J. F., Melin, J. A. and Vanoverschelde, J. L. J. 2001. Desctruction of contrast microbubbles by ultrasound: Effects on myocardial function, coronary perfusion pressure, and microvascular integrity. Circulation 104: 461-466. [Medline] [CrossRef]
7. Barrett, B. J. and Carlisle, E. J. 1993. Metaanalysis of the relative nephrotoxicity of high-and lowosmolality iodinated contrast media. Radiology 188: 171-178. [Medline]
8. Bergmeyer, H., Gawehn, K. and Grasse, M. 1974. Enzyme as biochemical reagents. pp. 438-358. In: Methods of Enzyme Analysis (Bergmeyer, H. V. ed.), Academic Press, New York.
9. Bieber, L. L. 1988. Carnitine. Ann. Rev. Biochem. 57: 261-283. [Medline] [CrossRef]
10. 2-Adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am. J. Physiol. Renal Physiol. 295: 741-748. [CrossRef]
11. Binienda, Z., Simmons, C., Hussain, S., Slikker, W. Jr. and Ali, S. F. 1998. Effect of acute exposure to 3-nitropropionic acid on activities of endogenous antioxidants in the rat brain. Neurosci. Lett. 251: 173-176. [Medline] [CrossRef]
12. Binienda, Z. K. and Ali, S. F. 2001. Neuroprotective role of l-carnitine in the 3-nitropropionic acid induced neurotoxicity. Toxicology Letters 125: 67-73. [Medline] [CrossRef]
13. Brevetti, G. and Perna, S. 1992. Metabolic and clinical effects of lcarnitine in peripheral vascular disease. pp. 359-378. In: l-carnitine and İts Role in Medicine: From Function to Therapy (Ferrari, R., DiMauro, S. and Sherwood, G. eds.), Academic Press, London.
14. Calò, L. A., Pagnin, E., Davis, P. A., Semplicini, A., Nicolai, R., Calvani, M. and Pessina, A. C. 2006. Antioxidant effect of l-carnitine and its short chain esters: Relevance for the protection from oxidative stress related cardiovascular damage. Int. J. Cardiol. 107: 54-60. [Medline] [CrossRef]
15. Colbay, M., Yuksel, S., Uslan, I., Acarturk, G., Karaman, O., Bas, O., Mollaoglu, H., Yagmurca, M. and Ozen, O. A. 2010. Novel approach for the prevention of contrast nephropathy. Exp. Toxicol. Pathol. 62: 81-89. [Medline] [CrossRef]
16. Conover, W. J. 1980. Practical Nonparametric Statistics, 2nd ed., John Wiley & Sons, New York.
17. Davidson, C., Stacul, F., McCullough, P. A., Tumlin, J., Adam, A., Lameire, N. and Becker, C. R. 2006. Contrast medium use. Am. J. Cardiol. 98: 42-58. [CrossRef]
18. Duan, S. B., Wang, Y. H., Liu, F. Y., Xu, X. Q., Wang, P., Zou, Q. and Peng, Y. M. 2009. The protective role of telmisartan against nephrotoxicity i{dotless}nduced by X-ray contrast media in rat model. Acta Radiol. 50: 754-759. [Medline] [CrossRef]
19. Ferrari, C. K. B. 2007. Functional foods and physical activities in health promotion of aging people. Maturitas 58: 327-339. [Medline] [CrossRef]
20. Fishman, E. K. and Reddan, D. 2008. What are radiologists doing to prevent contrast-induced nephropathy compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography. Acta Radiol. 49: 310-320. [Medline] [CrossRef]
21. Fridovich, I. 1995. Superoxide radical and superoxide dismutases. Ann. Rev. Biochem. 64: 97-112. [Medline] [CrossRef]
22. Gülcin, I. 2006. Antioxidant and antiradical activities of Lcarnitine. Life Sci. 78: 803-811. [Medline] [CrossRef]
23. Görür, S., Baǧdatoǧlu, O. T. and Polat, G. 2005. Protective effect of L-carnitine on renal ischaemia-reperfusion injury in the rat. Cell Biochem. Funct. 23: 151-155. [Medline] [CrossRef]
24. Hizoh, I. and Haller, C. 2002. Radiocontrast-induced renal tubular cell apoptosis: hypertonic versus oxidative stres. Invest. Radiol. 37: 428-434. [Medline] [CrossRef]
25. Hoppel, C. 2003. The role of carnitine in normal and altered fatty acid metabolism. Am. J. Kidney Dis. 41: 4-12. [Medline] [CrossRef]
26. Idée, J. M., Pines, E., Prigent, P. and Corot, C. 2005. Allergylike reactions to iodinated contrast agents. A critical analysis. Fundam. Clin. Pharmacol. 19: 263-281. [Medline] [CrossRef]
27. Imlay, J. A. 2003. Pathways of oxidative damage. Annu. Rev. Microbiol. 57: 395-418. [Medline] [CrossRef]
28. Jafar, T. H., Jafary, F. H., Jessani, S. and Chaturvedi, N. 2005. Heart disease epidemic in Pakistan: women and men at equal risk. Am. Heart J. 150: 221-226. [Medline] [CrossRef]
29. Katholi, R. E., Woods, W. T. Jr., Taylor, G. J., Deitrick, C. L., Womack, K. A., Katholi, C. R. and McCann, W. P. 1998. Oxygen free radicals and contrast nephropathy. Am. J. Kidney Dis. 32: 64-71. [Medline] [CrossRef]
30. Kelly, G. S. 1998. L-Carnitine: therapeutic applications of a conditionally-essential amino acid. Altern. Med. Rev. 3: 345-360. [Medline]
31. Knebel, F., Schimke, I., Eddicks, S., Walde, T., Ziebig, R., Schattke, S., Baumann, G. and Borges, A. C. 2005. Does contrast echocardiography induce increases in markers of myocardial necrosis, inflammation and oxidative stress suggesting myocardial injury? Cardiovascular Ultrasound 3: 21. [Medline] [CrossRef]
32. Kum, C., Kiral, F., Sekkin, S., Seyrek, K. and Boyacioglu, M. 2007. Effects of xylene and formaldehyede inhalation on oxidative stres in adult and developing rats livers. Exp. Anim. 56: 35-42. [Medline] [CrossRef]
33. Kumaran, S., Deepak, B., Naveen, B. and Panneerselvam, C. 2003. Effects of levocarnitine on mitochondrial antioxidant systems and oxidative stress in aged rats. Drugs R&D. 4: 141-147. [Medline] [CrossRef]
34. McCullough, P. A., Bertrand, M. E., Brinker, J. A. and Stacul, F. 2006. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J. Am. Coll. Cardiol. 48: 692-699. [Medline] [CrossRef]
35. Mister, M., Noris, M., Szymczuk, J., Azzollini, N., Aiello, S., Abbate, M., Trochimowicz, L., Gagliardini, E., Arduini, A., Perico, N. and Remuzzi, G. 2002. Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidney Int. 61: 1064-1078. [Medline] [CrossRef]
36. Onbasili, A. O., Yeniceriglu, Y., Agaoglu, P., Karul, A., Tekten, T., Akar, H. and Discigil, G. 2007. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart 93: 698-702. [Medline] [CrossRef]
37. Ozgur, T., Tutanc, M., Zararsiz, I., Motor, S., Ozturk, O. H., Yaldiz, M. and Kurtgoz, O. Y. 2012. The protective effect of ebselen on radiocontrast-i{dotless}nduced nephrotoxicity. Renal Failure 34: 991-997. [Medline] [CrossRef]
38. Parfrey, P. S., Griffiths, S. and Barrett, B. 1989. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency or both: a prospective controlled study. N. Engl. J. Med. 320: 143-149. [Medline] [CrossRef]
39. Perrone, R. D., Madias, N. E. and Levey, A. S. 1992. Serum creatinine as an index of renal function: new insights into old concepts. Clin. Chem. 38: 1933-1953. [Medline]
40. Rihal, C. S., Textor, S. C., Grill, D. E., Berger, P. B., Ting, H. H., Best, P. J., Singh, M., Bell, M. R., Barsness, G. W., Mathew, V., Garratt, K. N. and Holmes, D. R. Jr. 2002. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105: 2259-2264. [Medline] [CrossRef]
41. Sanaei-Ardekani, M., Movahed, M. R., Movafagh, S. and Ghahramani, N. 2005. Contrast-induced nephropathy: a review. Cardiovasc. Revasc. Med. 6: 82-88. [Medline] [CrossRef]
42. Sandhu, C., Belli, A. M. and Oliveira, D. B. 2006. The role of Nacetylcysteine in the prevention of contrast-i{dotless}nduced nephrotoxicity. Cardiovasc. Intervent. Radiol. 29: 344-347. [Medline] [CrossRef]
43. Sun, Y., Oberley, L. W. and Li, Y. 1988. A simple for clinical assay of superoxide dismutase. Clin. Chem. 34: 497-500. [Medline]
44. Tamai, I. 2013. Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). Biopharm. Drug Dispos. 34: 29-44. [Medline] [CrossRef]
45. Tepel, M., Van Der Giet, M., Schwarzfeld, C., Laufer, U., Liermann, D. and Zidek, W. 2000. Prevention of radiographiccontrast-agent-induced reductions in renal function by acetylcysteine. N. Engl. J. Med. 343: 180-184. [Medline] [CrossRef]
46. Thangasamy, T., Jeyakumar, P., Sittadjody, S., Joyee, A. G. and Chinnakannu, P. 2009. L-Carnitine mediates protection against DNA damage in lymphocytes of aged rats. Biogerontology 10: 163-172. [Medline] [CrossRef]
47. Tietze, F. 1969. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem. 27: 502-522. [Medline] [CrossRef]
48. Tumlin, J., Stacul, F., Adam, A., Becker, C. R., Davidson, C., Lameire, N. and McCullough, P. A. 2006. Pathophysiology of contrastinduced nephropathy. Am. J. Cardiol. 98: 14-20. [CrossRef]
49. Uysal, N., Yalaz, G., Acikgoz, O., Gonenc, S. and Kayatekin, B. M. 2005. Effect of L-carnitine on diabetogenic action of streptozotocin in rats. Neuroendocrinol. Lett. 26: 419-422. [Medline]
50. Valko, M., Izakovic, M., Mazur, M., Rhodes, C. J. and Telser, J. 2004. Role of oxygen radicals in DNA damage and cancer incidence. Mol. Cell. Biochem. 266: 37-56. [Medline] [CrossRef]
51. Wiseman, H. and Halliwell, B. 1996. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem. J. 313: 17-29. [Medline]
52. Wong, P. C. Y., Li, Z., Guo, J. and Zhang, A. 2012. Pathophysiology of contrast-induced nephropathy. Int. J. Cardiol. 158: 186-192. [Medline] [CrossRef]
53. Yari, A., Asadi, M. H., Bahadoran, H., Dashtnavard, H., Imani, H. and Naghii, M. R. 2010. Cadmium toxicity in spermatogenesis and protective effects of L-carnitine in adult male rats. Biol. Trace Elem. Res. 137: 216-225. [Medline] [CrossRef]
54. Yoshida, S., Kamihata, H., Nakamura, S., Senoo, T., Manabe, K., Motohiro, M., Sugiura, T. and Iwasaka, T. 2009. Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J. Cardiol. 54: 192-198. [Medline] [CrossRef]
55. Yoshioka, T., Kawada, K., Shimada, T. and Mori, M. 1979. Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. Am. J. Obstet. Gynecol. 135: 372-376. [Medline]